ABBV vs JNJ: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
JNJ has more upside to fair value
(+5.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
JNJ |
| Current Price |
$261.70 |
$270.68 |
| Fair Value Estimate |
$259.04 |
$286.05 |
| Upside to Fair Value |
-1.0%
|
+5.7%
|
| Market Cap |
$462.4B |
$652.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
20.2x
|
| Price / Sales |
7.2x
|
6.7x
|
| Price / FCF |
23.6x
|
35.3x
|
| Revenue Growth YoY |
+10.2%
|
+6.6%
|
| Gross Margin |
71.5%
|
67.9%
|
| Operating Margin |
29.3%
|
26.8%
|
| Return on Equity |
-136.5%
|
25.7%
|
| Dividend Yield |
2.61% |
1.95% |
| FCF Yield |
4.25%
|
2.83%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
Accumulation Zones
| Metric |
ABBV |
JNJ |
| Zone Low |
$194.28 |
$214.54 |
| Zone High |
$220.18 |
$243.14 |
| In Buy Zone? |
No
|
No
|